cyrilzakka/clinical-trials huggingface dataset:
Effect of Intraoperative Neuromuscular Blockade on Postoperative Sore Throat and Hoarseness

Investigators assess and compare postoperative sore throat and hoarseness in the group using the muscle relaxant and not using it during the operation.

The muscle relaxant is usually used during the operation to maintain moderate relaxation but, it can't be used in the surgery to need eletrophysiological monitoring during the operation. In this sturdy, the investigators assess the postoperative sore throat and hoarseness and compare the effect of muscle relaxant in the group using the muscle relaxant and not using it in terms of the incidence and severity of postoperative sore throat and hoarseness.

Eligibility Criteria:
Inclusion criteria

* patients scheduled to undergo elective lumbar spinal surgery Exclusion criteria
* known or predicted difficult airway
* neuromuscular diseases
* hepatic or renal dysfunction
* diseases or anatomical abnormalities in the neck, larynx, or pharynx
* requirement for postoperative mechanical ventilation
Exercise Following Autologous Peripheral Blood Stem Cell Transplantation

The study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-70
* Hematological disease
* Treatment with high-dose chemotherapy followed by autologous stem cell transplantation
* Understanding of written German

Exclusion Criteria:

* Cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be aggravated by exercise
* Pathological stress-ECG at admission
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver

Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with Nonalcoholic fatty liver


Eligibility Criteria:
Inclusion Criteria:

* 20 years of age and older, Male or female patients
* Chronic hepatitis B patients with Nonalcoholic fatty liver
* Patients who use oral anti-diabetic drug or drugs for hyperlipemia without any change in drug dosage within 2 month before screening visit
* Patients who have been explained about the trial and agreed to the consent
* Patients who agree with the approved method of contraception during the clinical trial

Exclusion Criteria:

* Patients with hepatitis C virus, hepatitis D virus or human immunodeficiency virus
* Patients who has a history of liver transplantation or Child-Pugh score \>=8
* Alpha-fetoprotein (AFP) \> 50 ng/mL or Hepatocellular Carcinoma (HCC) patients
* Patients who have taken Besifovir or Vemlidy
* Among the patients treated with immunosuppressive drug within 6 months before screening, suspected case of the declined immunity in the opinion of the investigator
* Chronic alcoholism (Significant alcohol consumption: male \> 210 g/week, female\> 140 g/week)
* Patients who take drugs that can cause hepatic steatosis
* Patient diagnosed with a malignant tumor within 5 years before screening or relapsed patient
* Patients with uncontrolled diabetes mellitus (HbA1c \> 9%) or using insulin
* Patients who participate in other clinical trials or is supposed to do so during the study period
* Pregnant or breast-feeding women or women who have plan to be pregnant.
* Patients with a history of hypersensitivity to the test drug or the components of the test drug
* Patients with moderate or severe renal impairment
* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
* History within the past one years or presence of drug abuse or alcoholism.
* Patient has serious disease judged by investigator such as heart failure, renal failure, and pancreatitis
* Patient has liver diseases except chronic hepatitis B (i.e. hematochromatosis, alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin deficiency etc.)
* Patient has history of organ transplantation
* Patient concerned about the decline in daily activity or not able to understand the objectives and methods due to the psychiatric problems
* Patients who are considered to be unacceptable in this study under the opinion of the investigator.
The Effect of Escitalopram in PCOS

In a randomized study the investigators aim to characterize the effect of antidepressive medicine on quality of life, body composition, adrenal activity and glucose metabolism in PCOS.

PCOS is a common endocrine disorder characterized by adrenal and ovarian hyperandrogenaemia, anovulation and insulin resistance. The pathogenesis of PCOS may be described by a vicious cycle involving insulin resistance which stimulates ovarian and adrenal hyper androgenaemia and leads to abdominal obesity, causing increased risk for diabetes and cardiovascular disease. Adrenal hyperactivity is associated with depression. Antidepressive medicine may normalize pituitary-adrenal activity and in animal studies antidepressive medicine improved adrenal hyperactivity and normalized insulin sensitivity.

Clinical study Effects of antidepressive treatment on quality of life, insulin sensitivity and cortisone metabolism in PCOS.

Hypothesis Participants with PCOS have increased hypothalamic-pituitary-adrenal activity compared to healthy women. Antidepressive treatment improves quality of life, cortisone and glucose turnover.

Design A randomized controlled study in 40 PCOS patients who are treated with cipralex or placebo for 12 weeks. Before and after the treatment period the patients have a physical examination, a whole body dexa scan and fasting blood samples. Hypothalamic-pituitary-adrenal is measured by 24 hour samples of cortisone metabolites, 60 minutes ACTH test with basal and stimulated measurement of cortisone and 17-hydroxyprogesterone. Glucose metabolism is examined by oral glucose tolerance test. Biopsies of muscle and fat are also performed.

Eligibility Criteria:
Inclusion Criteria:

* BMI \> 25 and \<5
* Age 18-45 years
* Two of the following 1: an/oligomenorhea, 2: Hirsutism or hyper androgenaemia, 3: PCO in trans vaginal ultrasound
* Other diagnoses excluded

Exclusion Criteria:

* Post menopausal
* Diabetes
* Eating disorder
* Psychiatric disorder
* Usage of oral anticonceptives or metformin
* Pregnancy or planned pregnancy in the treatment period
* Non-caucasian
* Epilepsy
* Allergy to the medicine
ENB for the Diagnosis of PPNs:a Real World Study

The study is designed as a multi-center prospective trial of ENB for the diagnosis of peripheral pulmonary nodules in the real world. The purpose of the study is to identify the optimal method of using ENB.

The study will be conducted at no less than 5 clinical centers. Patients with peripheral pulmonary nodules suspicious for malignancy will be enrolled in the study. ENB will be performed with/without other guided bronchoscopy techniques and/or ROSE. Different biopsy methods will be recorded as well. The primary endpoint is the diagnostic yield of ENB. The secondary endpoints include factors affecting diagnostic yield, operation time, complications, safety and so on.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who are older than 18 year-old.
2. Chest CT shows peripheral pulmonary nodule (8mm\<longest diameter≤30mm) suspicious for malignant that needs to be confirmed by pathology. The nodule is surrounded by lung parenchyma and invisible with standard bronchoscopy.
3. Patients who agree to undergo bronchoscopy without any contraindications.
4. Patients who have good compliance and sign informed consent.

Exclusion Criteria:

1. Presence of concomitant endobronchial lesion during the brochoscopy procerdure.
2. Severe cardiopulmonary dysfunction and other indications that can't receive bronchoscopy.
Effects of a Multifactorial Intervention to Reduce Physical Restraints for Care Providers in Nursing Homes

Scholars from around the world have been strongly advocating restraint-free care in long-term care institutions. Therefore, the aim of this study was to evaluate the effects of a multifactorial intervention to reduce physical restraints for care providers in nursing homes.

In Taiwanese nursing homes, the use of physical restraints on residents as a protective measure is fairly common. However, physical restraints can be seen as a violation of human rights, and there is no guarantee of the effectiveness or safety of such physical restraints.This study was to evaluate the effects of a multifactorial intervention to reduce physical restraints for care providers in nursing homes. A cluster randomized controlled trial was conducted using pretest-posttest control group design. A purposive sampling of participants was chosen from care providers of 6 nursing home institutions in Taiwan, who were then randomly assigned to the experimental group (3 nursing homes) or the control group (3 nursing homes). The experimental group underwent multifactorial interventions to reduce physical restraint.

Eligibility Criteria:
Inclusion Criteria:

* A full-time care provider
* Worked in a nursing home for more than three months
* Care providers have imposed physical restraints on elderly residents aged 60 or above Within the last month.

Exclusion Criteria:

• can't speak or read chinese, Vietnamese, Indonesian
Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

MDS are a diverse group of hematopoietic malignancies, which mainly occur in patients over 75 years of age. Incidence rate in 2012 in France was more than 6 cases per 100 000 person-years. MDS are characterized by ineffective haematopoiesis causing cytopenia, and by leukemic transformation. The disease is heterogeneous, its pathophysiology complex and clinical evolution variable.The few data available on MDS patients show how difficult it is to understand MDS, its prognosis and the reasons for prescribing or not some treatments. In the context of a highly complex potentially lethal disease such as MDS, it is of utmost importance to optimize the information conveyed to patients. Particularly, 70.5% of MDS patients surveyed in our developmental study would have preferred more information about prognosis at diagnosis disclosure.

A simple intervention based on the use of a question prompt list (QPL), would greatly improve the information process by helping patients to express their main concerns at their medical consultations. Cultural differences may exist in the appraisal of QPLs and QPLs have not yet been widely used in France.

However, in line with the previous results available in the literature and in a context a priori favourable to the use of such an instrument, the investigators hypothesise that use of a QPL will increase MDS patients' expressions of concerns and questions at their medical consultations. Particularly the investigators assume that the discussion about prognosis will be facilitated, without increasing anxiety because patients remain free to ask or not for such information. The use of QPLs would also be a way to limit social inequalities related to insufficient information and to encourage patient-doctor communication and meeting of patient preferences which could lead to better health outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Patients newly referred for a MDS in one of the participating centres
* Older than 18
* Able to answer a self-administered questionnaire
* Having signed an informed consent
* affiliated to the French Social Security System

Exclusion Criteria:

* emergency,patients deprived of liberty or placed under the authority of a tutor
Inflammatory Resolution in Cardiometabolic Health and Disease

The specific aim of this study is to determine molecular pathways that differentiate metabolically healthy vs unhealthy human phenotypes, and to investigate the therapeutic potential of pro-resolving lipids. Investigators will recruit volunteers that are metabolically healthy or unhealthy that fall within three BMI ranges: lean (18.-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and obese (\>30.0 kg/m2). Investigators hypothesize that metabolically healthy individuals have a superior endogenous capacity to regulate an inflammatory/resolving response.


Eligibility Criteria:
Inclusion Criteria:

* Informed signed consent has been obtained from the volunteer.
* The volunteer has a BMI greater than 18.5 kg/m2
* Men and women over the age of 18 are included.

Exclusion Criteria:

* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.
* An MD determines that the individual is on too many medications to participate.
* The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.
* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.
* The individual has some form of chronic inflammation.
* The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).
* The individual uses immunosuppressive drugs (e.g., methotrexate).
* The individual regularly consumes fish oils (omega 3).
* The individual has significant gastrointestinal problems.
* The individual smokes or uses chewing tobacco.
* The individual has been drinking alcohol two days before the study visit.
* The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination.
* The individual does not follow instructions given in the research study.
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is an immune mediated life-threatening disease. There is no uniform recommendation for salvage treatment of HLH. Based on the results of current clinical trials, the marketing situation of the drug in China, and the use requirements of pegylated recombinant human granulocyte stimulating factor(PEG-rhG-CSF), this study was conducted in patients who received the DEP rescue therapy or dexamethasone combined with VP-16 maintenance therapy. The aim of this study was to evaluate the efficacy and safety of PEG-rhG-CSF(Jinyouli®) for the recovery of neutropenia after chemotherapy in patients with hemophagocytic syndrome.


Eligibility Criteria:
Inclusion criteria：

1. Age ≥ 18 years old, ≤ 70 years old;
2. Patients with hemophagocytic syndrome diagnosed by HLH-2004 diagnostic criteria;
3. Patients who plan to receive rescue treatment or maintenance treatment;
4. The expected survival time is more than 1 month;
5. Patients sign informed consent form.

Exclusion Criteria：

1. Patients who have received bone marrow or hematopoietic stem cell transplantation in the past 3 months;
2. Patients with brain metastases;
3. Patients who are allergic to this product or other biological products derived from genetic engineering E. coli;
4. People with mental or nervous system disorders who cannot cooperate;
5. Pregnant or lactating female patients; women who refuse to accept contraceptive measures ;
6. Researchers determine unsuited to participate in this trial.
Compare the Quadriceps Function of Adductor Canal Block Versus Femoral Nerve Block With Electromyography Following Total Knee Arthroplasty

Adductor canal block and femoral nerve block are the most commonly used nerve blocks for pain control after total knee arthroplasty. The block area for adductor canal is a sensory branch near the knee area, which can potentially reduce the effect of motor blockage of quadriceps muscle. We try to proof adductor canal block can reduce the pain level after surgery effectively and preserve the muscle power of quadriceps muscle. Therefore, the rehabilitation course can be reduced and further lowering the risks of falling and complications.


Eligibility Criteria:
Inclusion Criteria:

* Age at least 50 years old, not exceed 100 years old
* Diagnosed Primary Knee Osteoarthritis
* Accepted Total Knee Arthroplasty

Exclusion Criteria:

* Diagnosed Osteonecrosis
* Diagnosed inflammatory Arthritis、Rheumatoid Arthritis
* Accepted Revision Total Knee Arthroplasty
* Quadriceps muscle rupture, suture or repair history
* Neurological or orthopedic disorders that could affect quadriceps muscle power
* Allergy to amide anesthetics
* Patients who cannot obey or follow directions
EBUS Score Validation for Malignancy

Surgical removal of a tumour in the lung offers the best chance for survival in early stage lung cancers. One main criteria of surgical eligibility is the absence of cancer spread to the lymph nodes; rendering the staging process extremely important. The evaluation of these lymph nodes is thought to be best completed using Endobronchial Ultrasound (EBUS), a procedure in which several lymph nodes are sampled and send to pathology to determine whether or not it is malignant. More recently, studies have observed that there are clear differences in the characteristics of cancerous and benign (non-cancerous) lymph nodes, and so there has been great interest in creating a list of criteria that can determine whether a node is malignant. This study aims to prospectively validate a previously proposed score based on observed characteristics of lymph nodes during an EBUS procedure relating to pathology-confirmed results. To test this, the results of the lymph node samples and the observed score will be compared for agreement. If the investigators find that the scoring system can accurately predict which lymph nodes are cancerous, it would provide the evidence to establish the score as a standard procedure during cancer staging.


Eligibility Criteria:
Inclusion Criteria:

* Must be diagnosed with confirmed or suspected lung cancer and be undergoing EBUS diagnosis/staging

Exclusion Criteria:

* N/A
Association Between Triglycerides Glucose Ratio With HOMA -IR as Indicators of Insulin Resistance in Obese Adults

The aim of the present study was to investigate the correlation between the triglyceride/glucose index (TyG index) and homeostasic model assessment of insulin resistance (HOMA-IR) to predict insulin resistance (IR) in obese adults

Obesity is a chronic disease that has an increasing prevalence in both developed and developing countries and affects adults and children\[1\] Obesity is an important risk factor for the development of some chronic diseases such as insulin resistance, hypertension, and type 2 diabetes \[2\]

. Insulin sensitivity is inversely related to body mass index and body fat. Insulin resistance can be defined as impairment of the normal biological response to both endogenous and exogenous insulin. One of the primary defects underlying the development of type 2 diabetes is thought to be insulin resistance. So, it is present in 85% of these patients with Type 2 DM. It is also related to the pathogenesis of many illnesses which includes coronary heart disease, and hypertension\[3\] Early detection of insulin resistance (IR) is important to prevent the development of cardiometabolic diseases such as Type 2 Diabetes Mellitus, metabolic syndrome, and coronary heart disease. The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index, which has high sensitivity and specificity, has been shown to be more useful in estimating the risk of insulin resistance, instead of more invasive, complex, and expensive direct tests such as pancreatic suppression test and hyperinsulinemic-euglycemic glucose clamp technique \[4\] HOMA-IR is an approved method for evaluating insulin resistance using fasting glucose and insulin levels and is widely used in clinical practice \[5\].

Triglyceride glucose (TyG) index is a novel marker, which has been demonstrated to have a high sensitivity and specificity in identifying insulin resistance \[6\].

Recently, the use of the triglyceride glucose (TyG) index, a product of fasting glucose and triglyceride are more easily accessible assessment tools both at the outpatient clinics and at the community level, and are low cost \[7\].

Eligibility Criteria:
Inclusion Criteria:

* Any obese adult (18 years or older) with BMI greater than or equal 30 of both sexes admitted to assiut unversity hospitals and clinics

Exclusion Criteria:

* Cases \<18 years old
* Cases with BMI \< 30
* Adult with endocrine abnormatilies under treatment for DM ,hypertension , dyslipidemia
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

Primary objective:

To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline).

Secondary objectives:

* To assess the effect on weight loss and weight maintenance; sustained effect following a washout period, effect on other markers of glycemic control (fasting glucose, fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG),
* To assess the effect on quality of life
* To evaluate long term safety and tolerability.

The total duration per patient will be approximately 38 months including a 30-month double-blind treatment period.

Eligibility Criteria:
Inclusion Criteria:

* No previous history of treatment for type 2 diabetes.
* Diagnosis of :

  * Impaired Glucose Tolerance (IGT) based on one oral glucose tolerance test (OGTT) and defined as a 2 hour post-challenge glucose (after a 75-g Oral Glucose Tolerance Test) \> 140 mg/dL (7.8 mmol/L) but \< 200 mg/dL (11.1 mmol/L), at the screening visit.
  * And / or impaired fasting glucose (IFG) based on a Fasting Plasma Glucose (FPG) ³ 100 mg/dL (5.6 mmol/L) and \< 126 mg/dL (7.0 mmol/L), at the screening visit.

Exclusion Criteria:

* Absence of effective contraceptive method for females of childbearing potential.
* Presence of any clinically significant endocrine disease according to the Investigator.Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit.
* Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
* Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
* Related to laboratory findings:

  * positive test for hepatitis B surface antigen and/or hepatitis C antibody;
  * Positive urine pregnancy test in females of childbearing potential ;
  * Thyroid-stimulating hormone (TSH) and free T4 outside central laboratory normal range.
* Related to previous or concomitant medications:

  * Within 3 months prior to screening visit and/or during the screening period:

    * anti-obesity drugs (e.g., sibutramine, orlistat, herbal preparations, etc),
    * systemic long-acting corticosteroids; prolonged use (more than 10 days) of systemic corticosteroids;